메뉴 건너뛰기




Volumn 27, Issue 1, 2013, Pages

Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: Evidence from the Italian Psocare Registry

(371)  Gisondi, P a   Cazzaniga, S b   Chimenti, S c   Giannetti, A d   MacCarone, M e   Picardo, M f   Girolomoni, G a   Naldi, L b   Griseta, V g   Miracapillo, A g   Azzini, M h   Mocci, L h   Michelini, M h   Offidani, A i   Bernardini, L i   Campanati, A i   Ricotti, G j   Giacchetti, A j   Norat, M k   Gualco, F k   more..


Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; ANTIPSORIASIS AGENT; ASPARTATE AMINOTRANSFERASE; CREATININE; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; TRIACYLGLYCEROL;

EID: 84872852757     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04450.x     Document Type: Article
Times cited : (82)

References (27)
  • 2
    • 22144490239 scopus 로고    scopus 로고
    • Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: Results from an Italian case-control study
    • et al.
    • Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125: 61-67.
    • (2005) J Invest Dermatol , vol.125 , pp. 61-67
    • Naldi, L.1    Chatenoud, L.2    Linder, D.3
  • 3
    • 72049101867 scopus 로고    scopus 로고
    • Comorbidities in patients with psoriasis
    • e1-9.
    • Gottlieb AB, Dann F,. Comorbidities in patients with psoriasis. Am J Med 2009; 122: 1150. e1-9.
    • (2009) Am J Med , vol.122 , pp. 1150
    • Gottlieb, A.B.1    Dann, F.2
  • 4
    • 77953611927 scopus 로고    scopus 로고
    • Psoriasis and systemic inflammatory diseases: Potential mechanistic links between skin disease and co-morbid conditions
    • et al.
    • Davidovici BB, Sattar N, Jörg PC, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010; 130: 1785-1796.
    • (2010) J Invest Dermatol , vol.130 , pp. 1785-1796
    • Davidovici, B.B.1    Sattar, N.2    Jörg, P.C.3
  • 5
    • 67649202177 scopus 로고    scopus 로고
    • Psoriasis and atherothrombotic diseases: Disease-specific and non-disease-specific risk factors
    • Gisondi P, Girolomoni G,. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin Thromb Hemost 2009; 35: 313-324.
    • (2009) Semin Thromb Hemost , vol.35 , pp. 313-324
    • Gisondi, P.1    Girolomoni, G.2
  • 6
    • 69949157317 scopus 로고    scopus 로고
    • Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis
    • Gisondi P, Targher G, Zoppini G, Girolomoni G,. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 758-764.
    • (2009) J Hepatol , vol.51 , pp. 758-764
    • Gisondi, P.1    Targher, G.2    Zoppini, G.3    Girolomoni, G.4
  • 7
    • 34250674798 scopus 로고    scopus 로고
    • Prevalence of metabolic syndrome in patients with psoriasis: A hospital-based case-control study
    • et al.
    • Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73.
    • (2007) Br J Dermatol , vol.157 , pp. 68-73
    • Gisondi, P.1    Tessari, G.2    Conti, A.3
  • 8
    • 17644376546 scopus 로고    scopus 로고
    • Traditional therapies in the management of moderate to severe chronic plaque psoriasis: An assessment of the benefits and risks
    • Naldi L, Griffiths CE,. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 2005; 152: 597-615.
    • (2005) Br J Dermatol , vol.152 , pp. 597-615
    • Naldi, L.1    Griffiths, C.E.2
  • 9
    • 34247397925 scopus 로고    scopus 로고
    • Elevated triglyceride and cholesterol levels after intravenous antitumour necrosis factor-alpha therapy in a patient with psoriatic arthritis and psoriasis vulgaris
    • Antoniou C, Dessinioti C, Katsambas A, Stratigos AJ,. Elevated triglyceride and cholesterol levels after intravenous antitumour necrosis factor-alpha therapy in a patient with psoriatic arthritis and psoriasis vulgaris. Br J Dermatol 2007; 156: 1090-1091.
    • (2007) Br J Dermatol , vol.156 , pp. 1090-1091
    • Antoniou, C.1    Dessinioti, C.2    Katsambas, A.3    Stratigos, A.J.4
  • 10
    • 57049089069 scopus 로고    scopus 로고
    • Liver toxicity of TNF-α antagonists
    • Dominique L,. Liver toxicity of TNF-α antagonists. Joint Bone Spine 2008; 75: 636-638.
    • (2008) Joint Bone Spine , vol.75 , pp. 636-638
    • Dominique, L.1
  • 11
    • 77649299313 scopus 로고    scopus 로고
    • Prevalence of overweight and obesity in Italy (2001-2008): Is there a rising obesity epidemic?
    • et al.
    • Micciolo R, Di Francesco V, Fantin F, et al. Prevalence of overweight and obesity in Italy (2001-2008): is there a rising obesity epidemic? Ann Epidemiol 2010; 20: 258-264.
    • (2010) Ann Epidemiol , vol.20 , pp. 258-264
    • Micciolo, R.1    Di Francesco, V.2    Fantin, F.3
  • 12
  • 13
    • 0026795571 scopus 로고
    • Elevation of fasting serum lipids in patients treated with low-dose cyclosporine for severe plaque-type psoriasis. An assessment of clinical significance when viewed as a risk factor for cardiovascular disease
    • et al.
    • Stiller MJ, Pak GH, Kenny C, et al. Elevation of fasting serum lipids in patients treated with low-dose cyclosporine for severe plaque-type psoriasis. An assessment of clinical significance when viewed as a risk factor for cardiovascular disease. J Am Acad Dermatol 1992; 27: 434-438.
    • (1992) J Am Acad Dermatol , vol.27 , pp. 434-438
    • Stiller, M.J.1    Pak, G.H.2    Kenny, C.3
  • 14
    • 0025651827 scopus 로고
    • Management of patients and side effects during cyclosporine therapy for cutaneous disorders
    • Fradin MS, Ellis CN, Voorhees JJ,. Management of patients and side effects during cyclosporine therapy for cutaneous disorders. J Am Acad Dermatol 1990; 23: 1265-1273.
    • (1990) J Am Acad Dermatol , vol.23 , pp. 1265-1273
    • Fradin, M.S.1    Ellis, C.N.2    Voorhees, J.J.3
  • 15
    • 77956190766 scopus 로고    scopus 로고
    • A systematic review of the effect of TNF-α antagonists on lipid profiles in patients with rheumatoid arthritis
    • Pollono EN, Lopez-Olivo MA, Martinez Lopez JA, Suarez-Almazor ME,. A systematic review of the effect of TNF-α antagonists on lipid profiles in patients with rheumatoid arthritis. Clin Rheumatol 2010; 29: 947-955.
    • (2010) Clin Rheumatol , vol.29 , pp. 947-955
    • Pollono, E.N.1    Lopez-Olivo, M.A.2    Martinez Lopez, J.A.3    Suarez-Almazor, M.E.4
  • 16
    • 70449532376 scopus 로고    scopus 로고
    • Marked hypertriglyceridemia upon treatment with etanercept
    • Haroon M, Devlin J,. Marked hypertriglyceridemia upon treatment with etanercept. Joint Bone Spine 2009; 76: 570-571.
    • (2009) Joint Bone Spine , vol.76 , pp. 570-571
    • Haroon, M.1    Devlin, J.2
  • 17
    • 36148952208 scopus 로고    scopus 로고
    • Hypertriglyceridaemia during treatment with adalimumab in psoriatic arthritis
    • Stinco G, Piccirillo F, Patrone P,. Hypertriglyceridaemia during treatment with adalimumab in psoriatic arthritis. Br J Dermatol 2007; 157: 1273-1274.
    • (2007) Br J Dermatol , vol.157 , pp. 1273-1274
    • Stinco, G.1    Piccirillo, F.2    Patrone, P.3
  • 18
    • 64749083236 scopus 로고    scopus 로고
    • Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference
    • Kalb RE, Strober B, Weinstein G, Lebwohl M,. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009; 60: 824-837.
    • (2009) J Am Acad Dermatol , vol.60 , pp. 824-837
    • Kalb, R.E.1    Strober, B.2    Weinstein, G.3    Lebwohl, M.4
  • 19
    • 0033524159 scopus 로고    scopus 로고
    • Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group
    • et al.
    • Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-1939.
    • (1999) Lancet , vol.354 , pp. 1932-1939
    • Maini, R.1    St Clair, E.W.2    Breedveld, F.3
  • 20
    • 0037018761 scopus 로고    scopus 로고
    • Maintenance infliximab for Crohn's disease: The ACCENT i randomised trial
    • et al. ACCENT I Study Group.
    • Hanauer SB, Feagan BG, Lichtenstein GR, et al., ACCENT I Study Group Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549.
    • (2002) Lancet , vol.359 , pp. 1541-1549
    • Hanauer, S.B.1    Feagan, B.G.2    Lichtenstein, G.R.3
  • 21
    • 85046882531 scopus 로고    scopus 로고
    • FDA Briefing document. Arthritis Advisory committee, http://www.fda.gov/ ohrms/dockets/ac/03/transcripts/3930T1.htm.
  • 22
    • 70249137988 scopus 로고    scopus 로고
    • European S3-guidelines on the systemic treatment of psoriasis vulgaris
    • et al.
    • Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl 2): 1-70.
    • (2009) J Eur Acad Dermatol Venereol , vol.23 , Issue.SUPPL. 2 , pp. 1-70
    • Pathirana, D.1    Ormerod, A.D.2    Saiag, P.3
  • 23
    • 77956044627 scopus 로고    scopus 로고
    • Long-term graft function changes in kidney transplant recipients
    • et al.
    • Marcén R, Morales JM, Fernández-Rodriguez A, et al. Long-term graft function changes in kidney transplant recipients. NDT Plus 2010; 3: ii2-ii8.
    • (2010) NDT Plus , vol.3
    • Marcén, R.1    Morales, J.M.2    Fernández-Rodriguez, A.3
  • 24
    • 3142619217 scopus 로고    scopus 로고
    • Cyclosporin in psoriasis clinical practice: An international consensus statement
    • et al.
    • Griffiths CE, Dubertret L, Ellis CN, et al. Cyclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol 2004; 150: 11-23.
    • (2004) Br J Dermatol , vol.150 , pp. 11-23
    • Griffiths, C.E.1    Dubertret, L.2    Ellis, C.N.3
  • 25
    • 77950596138 scopus 로고    scopus 로고
    • Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference
    • Rosmarin DM, Lebwohl M, Elewski BE, Gottlieb AB,. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2010; 62: 838-853.
    • (2010) J Am Acad Dermatol , vol.62 , pp. 838-853
    • Rosmarin, D.M.1    Lebwohl, M.2    Elewski, B.E.3    Gottlieb, A.B.4
  • 26
    • 33748665445 scopus 로고    scopus 로고
    • Relative risk of new-onset diabetes during the first year after renal transplantation in patients receiving tacrolimus or cyclosporine immunosuppression
    • Hoitsma AJ, Hilbrands LB,. Relative risk of new-onset diabetes during the first year after renal transplantation in patients receiving tacrolimus or cyclosporine immunosuppression. Clin Transplant 2006; 20: 659-664.
    • (2006) Clin Transplant , vol.20 , pp. 659-664
    • Hoitsma, A.J.1    Hilbrands, L.B.2
  • 27
    • 0037084090 scopus 로고    scopus 로고
    • Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets
    • Paty BW, Harmon JS, Marsh CL, Robertson RP,. Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets. Transplantation 2002; 73: 353-357.
    • (2002) Transplantation , vol.73 , pp. 353-357
    • Paty, B.W.1    Harmon, J.S.2    Marsh, C.L.3    Robertson, R.P.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.